Faulx Michael D, Mehra Reena, Reis Geovanini Glaucylara, Ando Shin-Ichi, Arzt Michael, Drager Luciano, Fu Michael, Hoyos Camilla, Hai Jo, Hwang Juey-Jen, Karaoguz Remzi, Kimoff John, Lee Pei-Lin, Mediano Olga, Patel Sanjay R, Peker Yüksel, Louis Pepin Jean, Sanchez-de-la-Torre Manuel, Sériès Frédéric, Stadler Stefan, Strollo Patrick, Tahrani A A, Thunström Erik, Yamauchi Motoo, Redline Susan, Phillips Craig L
Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Director, Sleep Disorders Research. Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Int J Cardiol Heart Vasc. 2022 Jul 19;42:101085. doi: 10.1016/j.ijcha.2022.101085. eCollection 2022 Oct.
Among international cardiologists it is unclear whether equipoise exists regarding the benefit of diagnosing and managing obstructive sleep apnea (OSA) to improve atrial fibrillation (AF) outcomes and whether clinical practice and equipoise are linked.
Between January 2019 and June 2020 we distributed a web-based 12-question survey regarding OSA and AF management to practicing cardiologists in 16 countries.
The United States, Japan, Sweden, and Turkey accounted for two-thirds of responses. 863 cardiologists responded; half were general cardiologists, a quarter electrophysiologists. Responses regarding treating OSA with CPAP to improve AF endpoints were mixed. 33% of respondents referred AF patients for OSA screening. OSA was diagnosed in 48% of referred patients and continuous positive airway pressure (CPAP) was prescribed for 59% of them. Nearly 70% of respondents believed randomized controlled trials (RCTs) of OSA treatment in AF patients were necessary and indicated willingness to contribute to such trials.
There was no clinical equipoise among surveyed cardiologists; a majority expressed certainty that combined OSA and AF treatment is superior to AF treatment alone for improving AF outcomes. However, a minority of surveyed cardiologists referred AF patients for OSA testing, and while half of screened AF patients had OSA, CPAP was prescribed in little more than half of them, reflecting the view that better clinical trial evidence is needed to support this practice. Our results underscore the need for larger, multi-national prospective studies of OSA treatment and AF outcomes to inform more uniform society guideline recommendations.
在国际心脏病专家中,对于诊断和管理阻塞性睡眠呼吸暂停(OSA)以改善房颤(AF)结局的益处是否存在 equipoise 尚不清楚,以及临床实践与 equipoise 是否相关也不明确。
在2019年1月至2020年6月期间,我们向16个国家的执业心脏病专家发放了一份基于网络的关于OSA和AF管理的12个问题的调查问卷。
美国、日本、瑞典和土耳其的回复占三分之二。863名心脏病专家回复;其中一半是普通心脏病专家,四分之一是电生理学家。关于使用持续气道正压通气(CPAP)治疗OSA以改善房颤终点的回复不一。33%的受访者将房颤患者转诊进行OSA筛查。在转诊患者中,48%被诊断为OSA,其中59%被开具了持续气道正压通气(CPAP)治疗。近70%的受访者认为有必要对房颤患者进行OSA治疗的随机对照试验(RCT),并表示愿意参与此类试验。
在接受调查的心脏病专家中不存在临床 equipoise;大多数人表示确定联合治疗OSA和AF比单独治疗AF在改善房颤结局方面更具优势。然而,少数接受调查的心脏病专家将房颤患者转诊进行OSA检测,虽然一半接受筛查的房颤患者患有OSA,但其中只有略多于一半的患者被开具了CPAP,这反映出需要更好的临床试验证据来支持这种做法。我们的结果强调需要进行更大规模的、多国前瞻性研究,以了解OSA治疗和房颤结局,从而为更统一的社会指南建议提供依据。